Cargando…
Optimizing the management of advanced non-small-cell lung cancer: a personal view
The management of advanced non-small-cell lung cancer (a-nsclc) is currently undergoing one of its rare paradigm shifts. Just as the nihilism of the 1970s gave way to the empiricism of the 1980s and 1990s, so the current decade has seen the first truly rational therapies based on informed design. In...
Autor principal: | Vincent, M.D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722061/ https://www.ncbi.nlm.nih.gov/pubmed/19672420 |
Ejemplares similares
-
Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
por: Tabchi, Samer, et al.
Publicado: (2017) -
The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer
por: Crombet Ramos, Tania, et al.
Publicado: (2021) -
Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
por: Martin, Claudio, et al.
Publicado: (2022) -
Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed?
por: Ayeni, O., et al.
Publicado: (2009) -
Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib
por: Melosky, B., et al.
Publicado: (2008)